Specifically, Actemra is indicated for patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation and is recommended for use as a single 60-minute intravenous infusion.
The company’s application was supported by the results of four randomised, controlled studies in more than 5,500 hospitalised which altogether showed that Actemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support.
